Recent studies showed that in patients with rheumatoid arthritis (RA), methotrexate administration diminished CVD risk by reducing several pro-inflammatory cytokines (IL-6, TNF-α) and CRP [14,15], purine biosynthesis, and may also stimulate the release of adenosine, all of which may lead to its anti-inflammatory properties [16,17]. Here, TNF is linked to rheumatoid arthritis.